Based on the key indicators related to Zoetis' liquidity, profitability, solvency, and operating efficiency, Zoetis Inc may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Zoetis' Property Plant And Equipment Gross is comparatively stable compared to the past year. Intangible Assets is likely to gain to about 1.4 B in 2024, whereas Total Assets are likely to drop slightly above 10.5 B in 2024. Key indicators impacting Zoetis' financial strength include:
Investors should never underestimate Zoetis' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Zoetis' cash flow, debt, and profitability to make informed and accurate decisions about investing in Zoetis Inc.
Cash And Equivalents
2.59 Billion
Zoetis
Select Account or Indicator
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Liabilities
Sale Purchase Of Stock
Change Receivables
Net Borrowings
Total Cashflows From Investing Activities
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Investments
Common Stock Shares Outstanding
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Cash And Short Term Investments
Net Receivables
Good Will
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Property Plant Equipment
Total Permanent Equity
Noncontrolling Interest In Consolidated Entity
Retained Earnings
Retained Earnings Total Equity
Short Term Investments
Additional Paid In Capital
Deferred Long Term Liab
Treasury Stock
Net Tangible Assets
Short Long Term Debt
Long Term Debt Total
Capital Surpluse
Non Current Liabilities Other
Deferred Long Term Asset Charges
Cash And Equivalents
Net Invested Capital
Net Working Capital
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Net Income Applicable To Common Shares
Minority Interest
Net Income From Continuing Ops
Non Recurring
Non Operating Income Net Other
Tax Provision
Net Interest Income
Reconciled Depreciation
Interest Income
Selling And Marketing Expenses
Probability Of Bankruptcy
Understanding current and past Zoetis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Zoetis' financial statements are interrelated, with each one affecting the others. For example, an increase in Zoetis' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Zoetis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Zoetis Inc. Check Zoetis' Beneish M Score to see the likelihood of Zoetis' management manipulating its earnings.
Zoetis Stock Summary
Zoetis competes with Emergent Biosolutions, Bausch Health, Neurocrine Biosciences, Teva Pharma, and Haleon Plc. Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 12100 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Zoetis' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Zoetis's current stock value. Our valuation model uses many indicators to compare Zoetis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zoetis competition to find correlations between indicators driving Zoetis's intrinsic value. More Info.
Zoetis Inc is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.31 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Zoetis Inc is roughly 3.23 . At this time, Zoetis' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zoetis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Zoetis Inc Systematic Risk
Zoetis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zoetis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Zoetis Inc correlated with the market. If Beta is less than 0 Zoetis generally moves in the opposite direction as compared to the market. If Zoetis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zoetis Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zoetis is generally in the same direction as the market. If Beta > 1 Zoetis moves generally in the same direction as, but more than the movement of the benchmark.
Zoetis Thematic Clasifications
Zoetis Inc is part of several thematic ideas from Obamacare Repeal to SRI Sustainable Growth. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Zoetis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zoetis' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Zoetis growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Zoetis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zoetis Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zoetis Inc based on widely used predictive technical indicators. In general, we focus on analyzing Zoetis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zoetis's daily price indicators and compare them against related drivers.
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.